Previous studies demonstrated that LSD1 protein and mRNA levels could act as biomarkers for patients with more aggressive tumors of breast cancer, prostate cancer, and neuroblastoma [18]–[20]. The gene discussed is KDM1A; the disease is prostate carcinoma.